Inovio Pharmaceuticals (NSDQ:INO) said today that it priced its underwritten public offering of 12.5 million shares of common stock at $6.00 apiece. The offering is expected to bring in nearly $75 million for the Plymouth Meeting, Penn.-based company. The offering, which is expected to close on July 25, includes a 30-day option for underwriters to buy […]
Funding Roundup
Inovio looks to raise $75m in public offering
Inovio Pharmaceuticals (NSDQ:INO) said yesterday that it is launching an underwritten public offering to sell $75 million shares of common stock. The Plymouth Meeting, Penn.-based company said it plans to grant underwriters an option to buy up to $11.3 million additional shares of common stock. Inovio is slated to use its newly-acquired funds to support general […]
CDC gives $12m to states to fight opioid epidemic
The Centers for Disease Control and Prevention said today that it plans to award more than $12 million this week to 23 states and the District of Columbia to support their efforts in tackling the opioid overdose epidemic. The funding comes from the fiscal year 2017 omnibus appropriations bill that became law in May. States […]
Provention Bio evaluates vaccine to prevent onset of T1D
Provention Bio said today that it licensed an enterovirus vaccine platform that it plans to evaluate as a way to prevent the onset of Type I diabetes by vaccinating against infection by a coxsackievirus B pathogen. Previous work has shown that CVB infection could be responsible for 50% of Type I diabetes cases worldwide, according […]
OpGen prices $10m public offering
OpGen (NSDQ:OPGN) said earlier this month that it priced a $10 million public offering of 25 million units of common stock and warrants at 40¢ apiece. The molecular diagnostics company said each common warrant has an exercise price of 43¢ per share and expires five years after issuance. The offering is slated to close tomorrow. […]
AntriaBio raises $13m for injectable, once-weekly insulin
AntriaBio (OTC:ANTB) said today that it closed a $13 million private placement, supported by Aju Pharm, Ildong Pharmaceutical Co. and Medici Investment Co. According to the deal, investors paid $1.00 per share of common stock. The Louisville, Colo.-based company said it plans to use the proceeds for general corporate purposes, including the Phase I study of its […]
Ionis-spinout Akcea prices IPO below expected range
Cambridge, Mass.-based Akcea Therapeutics priced its offering of 15.6 million shares at $8 apiece to reach its $125 million IPO target. The company initially priced an offering of 9.6 million shares at $12 to $14 per share. Akcea’s shares are slated to begin trading on the Nasdaq exchange today under the “AKCA.” The biotech is a […]
Carmell Therapeutics raises $4m for regenerative biomaterial
Carnegie Mellon spin-out Carmell Therapeutics said today that it closed a $4 million Series B financing round last month that it plans to use to bring its first product candidate to Phase III clinical development. Its Bone Healing Accelerant uses pooled plasma to boost the healing of bone and soft tissues. Current investors, including Pittsburgh […]
Google backs Decibel Therapeutics in big data hearing loss play
Decibel Therapeutics said today it landed an investment from GV, formerly Google Ventures. GV agreed to make an equity investment in the Boston-based company and lend its capabilities in big data sciences and analytics to Decibel’s efforts in developing therapies for hearing loss and tinnitus. “We are delighted to work with GV to amplify our […]
Delcath raises $2m in Series B stock sale
Delcath Systems (NSDQ:DCTH) has raised $2 million after selling 2,360 shares of Series B preferred stock at $1,000 per share to unnamed institutional investors, according to a regulatory filing. The company wrote that it plans to use the proceeds for general corporate purposes. Delcath is developing a system for liver-directed high dose chemotherapy, which involves a […]